Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Rosebud Biosciences Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to a distinct examiner and 1 distinct art unit. The presence of only an individual art unit suggests that the company's current biological innovations fall within a narrow administrative category at the patent office.
The busiest examiner, QIAN, CELINE X, is responsible for the pending office action. With only an individual examiner and art unit involved, the prosecution process is highly focused. Practitioners should prioritize understanding the specific feedback from QIAN, CELINE X, as this examiner is the sole individual currently reviewing the company's pending biotechnology applications.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| QIAN, CELINE X | 1 | 47.6% | +16.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18260220 | Methods and Compositions for Diagnosing and Treating Rare Genetic DIseases | QIAN, CELINE X | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18260220 | Methods and Compositions for Diagnosing and Treating Rare Genetic DIseases | QIAN, CELINE X | — |
| Art Unit | Apps |
|---|---|
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18260220 | Methods and Compositions for Diagnosing and Treating Rare Genetic DIseases | QIAN, CELINE X | 1699 | §101§102§103§112 | Non-Final OA | — | Pending | Jun 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial